Dissertations / Theses on the topic 'Vasodilators'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Vasodilators.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
D'Oyley, Heather M. "Vasodilators and venous tone." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/27871.
Full textMedicine, Faculty of
Anesthesiology, Pharmacology and Therapeutics, Department of
Graduate
Siddons, Thomas Edward. "The use of pulsed inhaled nitric oxide in the investigation and treatment of chronic disease affecting the pulmonary circulation." Thesis, University of Sheffield, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274966.
Full textTalbot, Nicola Maria. "Metal nitrosyl and organic nitrates as novel vasodilators." Thesis, University of Exeter, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.385724.
Full textWeldon, Hazel. "The synthesis of novel nitric oxide donors as potential vasodilators." Thesis, University of Exeter, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307295.
Full textLo, Sze-man Irene. "A comparison of the vasoactive metabolites in the interstitial space of oxidative or glycolytic muscles in anaesthetised rats /." Hong Kong : University of Hong Kong, 2000. http://sunzi.lib.hku.hk/hkuto/record.jsp?B21790838.
Full textHYNES, MICHAEL RAY. "ENDOTHELIUM-DEPENDENT RELAXATION OF BLOOD VESSELS." Diss., The University of Arizona, 1987. http://hdl.handle.net/10150/184134.
Full textReeves, Katherine Ann. "The cardiovascular actions of the isopropyl ester and other synthetic derivatives of palmitoyl carnitine." Thesis, University of Bath, 1995. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260252.
Full textJoseph, Emlyn Clive. "Pathogenesis of arteriopathy induced by PDE III inhibitors in the rat and dog." Thesis, Queen Mary, University of London, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307684.
Full textFirkin, Catherine R. "A biomimetic approach to the synthesis of xestospongin A." Thesis, University of Oxford, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389208.
Full text羅詩敏 and Sze-man Irene Lo. "A comparison of the vasoactive metabolites in the interstitial space of oxidative or glycolytic muscles in anaesthetised rats." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B31223138.
Full textWier, S. W. "A study of the action of some vasodilators in the rat and guinea-pig." Thesis, University of Manchester, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.374572.
Full textMcLeod, Janet Leigh, and janet mcleod@deakin edu au. "The natriuretic peptides and their receptors in the brain of the amphibian, Bufo marinus." Deakin University. School of Biological and Chemical Sciences, 1999. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20071024.112730.
Full textHeeneman, Sylvia. "Structural alterations in peripheral arteries during experimental heart failure opposing effects of vasoconstrictors and vasodilators /." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Maastricht University [Host], 1997. http://arno.unimaas.nl/show.cgi?fid=5813.
Full textFinch, Michael Brendan. "Haemodynamic effects of some peripheral vasodilators in normal man and in patients with Reynauds's syndrome." Thesis, Queen's University Belfast, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328044.
Full textSchrage, William. "Effects of hindlimb unweighting on soleus muscle resistance artery endothelial function and eNOS expression." free to MU campus, to others for purchase, 2001. http://wwwlib.umi.com/cr/mo/fullcit?p3013020.
Full textYin, Ning [Verfasser]. "Inhaled vasodilators as a new treatment strategy in pulmonary hypertension with left heart disease / Ning Yin." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2009. http://d-nb.info/1023580365/34.
Full textTsoporis, Jim. "Effects of arterial vasodilators on cardiovascular hypertrophy and sympathetic activity in normotensive Wistar and spontaneously hypertensive rats." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/NQ66241.pdf.
Full textGómez, Ortiz Edna Mireya [UNESP]. "Avaliação cardíaca de cães com degeneração valvar mixomatosa durante o emprego de enalapril, losartana, furosemida e suas combinações." Universidade Estadual Paulista (UNESP), 2011. http://hdl.handle.net/11449/89198.
Full textConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
A degeneração valvar mixomatosa (DVM) é a afecção cardíaca mais comum em cães. O tratamento da insuficiência cardíaca congestiva (ICC) decorrente da DVM baseia-se no uso de inibidores da enzima conversora de angiotensina - ECA. Antagonistas dos receptores de angiotensina II - ARAs promovem o bloqueio completo da angiotensina II, e são usados no tratamento de ICC em humanos, mas não é comum em cães. O objetivo desta pesquisa foi comparar as respostas clínicas de cães com DVM tratados com enalapril- ECA, losartana -ARAs, furosemida – diurético de alça ou suas combinações. Vinte e nove cães foram distribuídos em cinco grupos dependendo da classe de ICC (Ib ou II) e do tratamento: G1 - Ib, enalapril; G2 – Ib, losartana; G3 – II, enalapril + furosemida; G4 – II, losartana + furosemida; G5- II, enalapril + losartana. Realizou-se exame físico, e determinaramse medidas eletrocardiográficas e pressão arterial nos dias 0, 14, 28 e 56 após início dos tratamentos. Medida radiográfica - Vertebral Heart Size, e variáveis ecodopplercardiográficas obtiveram-se nos dias 0 e 56. Submeteram-se os dados a analise de variância com medidas repetidas. Não houve diferenças (P>0,05) nas variáveis ecodopplercardiográficas, eletrocardiográficas e radiográficas quando comparados cães tratados com enalapril, losartana e suas combinações, tanto com ICC da classe Ib quanto da II. Nos cães de todos os grupos houve diminuição (P> 0,05), a través do tempo, da Vertebral Heart Size e redução (P> 0,05) da duração da onda P e do complexo QRS. Concluiu-se que losartana atua de forma similar ao enalapril no tratamento inicial (primeiros 56 dias) de cães com DVM em fases Ib e II da ICC
Degenerative myxomatous mitral valve disease (DMMVD) is the most common cardiac disease in dogs. The treatment of congestive heart failure (CHF) due to DMMVD is based, among others, on the use of vasodilators, like angiotensin converting enzyme (ACE) inhibitors. Recently, other vasodilators such as angiotensin II receptor antagonists (ARAs) have been used in humans with CHF and have promoted a complete blockage of angiotensin II, but is not common in dogs. Thus, the purpose of this investigation was to compare clinical outcomes of enalapril- ACA , losartan - ARAs, furosemide loop diuretic and its combinations in the treatment of CHF in dogs with DMMVD. For this, 29 dogs were distributed into five groups regardless of class of CHF (Ib or II) and treatment: G1- Ib, enalapril; G2 – Ib losartan; G3 enlapril + furosemida; G4 losartan + furosemida; G5 enalapril + losartan. Physical examination, electrocardiographic examinations and determination of blood pressure were performed on day 0, 14, 28 and 56 after the begging of treatment, whereas radiographic and echocardiogram just at the day 0 and 56. Data was submitted to analysis of variance with repeated measures. there was no difference (P> 0.05) when comparing the dogs treated with enalapril and losartan and its combinations within the classes Ib and II for echoDopplercardiographic, electrocardiographic and radiographic parameters. The measuring radiographic Vertebral Heart Size was significant (P <0.05) decreased this variable to the time factor, of all groups and the P-wave and the QRS complex duration (P <0.05). It was concluded that losartan has a similar effect of enalapril in the initial treatment (first 56 days) in dogs with DMMVD class Ib and II of the CHF
Wathen, Christopher George. "Studies of the cardiovascular effects of inotropic agents and vasodilators on the pulmonary and systemic circulation in man." Thesis, University of Edinburgh, 1988. http://hdl.handle.net/1842/27032.
Full textGomez, Ortiz Edna Mireya. "Avaliação cardíaca de cães com degeneração valvar mixomatosa durante o emprego de enalapril, losartana, furosemida e suas combinações /." Jaboticabal : [s.n.], 2011. http://hdl.handle.net/11449/89198.
Full textBanca: Mirela Tinucci Costa
Banca: Wagner Luis Ferreira
Resumo: A degeneração valvar mixomatosa (DVM) é a afecção cardíaca mais comum em cães. O tratamento da insuficiência cardíaca congestiva (ICC) decorrente da DVM baseia-se no uso de inibidores da enzima conversora de angiotensina - ECA. Antagonistas dos receptores de angiotensina II - ARAs promovem o bloqueio completo da angiotensina II, e são usados no tratamento de ICC em humanos, mas não é comum em cães. O objetivo desta pesquisa foi comparar as respostas clínicas de cães com DVM tratados com enalapril- ECA, losartana -ARAs, furosemida - diurético de alça ou suas combinações. Vinte e nove cães foram distribuídos em cinco grupos dependendo da classe de ICC (Ib ou II) e do tratamento: G1 - Ib, enalapril; G2 - Ib, losartana; G3 - II, enalapril + furosemida; G4 - II, losartana + furosemida; G5- II, enalapril + losartana. Realizou-se exame físico, e determinaramse medidas eletrocardiográficas e pressão arterial nos dias 0, 14, 28 e 56 após início dos tratamentos. Medida radiográfica - Vertebral Heart Size, e variáveis ecodopplercardiográficas obtiveram-se nos dias 0 e 56. Submeteram-se os dados a analise de variância com medidas repetidas. Não houve diferenças (P>0,05) nas variáveis ecodopplercardiográficas, eletrocardiográficas e radiográficas quando comparados cães tratados com enalapril, losartana e suas combinações, tanto com ICC da classe Ib quanto da II. Nos cães de todos os grupos houve diminuição (P> 0,05), a través do tempo, da Vertebral Heart Size e redução (P> 0,05) da duração da onda P e do complexo QRS. Concluiu-se que losartana atua de forma similar ao enalapril no tratamento inicial (primeiros 56 dias) de cães com DVM em fases Ib e II da ICC
Abstract: Degenerative myxomatous mitral valve disease (DMMVD) is the most common cardiac disease in dogs. The treatment of congestive heart failure (CHF) due to DMMVD is based, among others, on the use of vasodilators, like angiotensin converting enzyme (ACE) inhibitors. Recently, other vasodilators such as angiotensin II receptor antagonists (ARAs) have been used in humans with CHF and have promoted a complete blockage of angiotensin II, but is not common in dogs. Thus, the purpose of this investigation was to compare clinical outcomes of enalapril- ACA , losartan - ARAs, furosemide loop diuretic and its combinations in the treatment of CHF in dogs with DMMVD. For this, 29 dogs were distributed into five groups regardless of class of CHF (Ib or II) and treatment: G1- Ib, enalapril; G2 - Ib losartan; G3 enlapril + furosemida; G4 losartan + furosemida; G5 enalapril + losartan. Physical examination, electrocardiographic examinations and determination of blood pressure were performed on day 0, 14, 28 and 56 after the begging of treatment, whereas radiographic and echocardiogram just at the day 0 and 56. Data was submitted to analysis of variance with repeated measures. there was no difference (P> 0.05) when comparing the dogs treated with enalapril and losartan and its combinations within the classes Ib and II for echoDopplercardiographic, electrocardiographic and radiographic parameters. The measuring radiographic Vertebral Heart Size was significant (P <0.05) decreased this variable to the time factor, of all groups and the P-wave and the QRS complex duration (P <0.05). It was concluded that losartan has a similar effect of enalapril in the initial treatment (first 56 days) in dogs with DMMVD class Ib and II of the CHF
Mestre
Kulczynska, Agnieszka. "N-hydroxyguanidines and related compounds as nitric oxide donors." Thesis, University of St Andrews, 2009. http://hdl.handle.net/10023/957.
Full textLunkes, Daniéle Sausen. "Interferência de vasodilatadores na hidrólise de nucleotídeos da adenina em plaquetas de pacientes hipertensos." Universidade Federal de Santa Maria, 2009. http://repositorio.ufsm.br/handle/1/11097.
Full textO processo trombogênico que afeta os pacientes hipertensos está associado com mecanismos regulatórios presentes no endotélio vascular. Esses mecanismos envolvem o fator de relaxamento do endotélio, as ectonucleotidases e íons cálcio. Considerando que os vasodilatadores atuam em ambos, na pressão sangüínea e na homeostase, foi avaliada a interferência de diferentes vasodilatadores na atividade da NTPDase de plaquetas de hipertensos e pacientes saudáveis, com o objetivo de verificar a sensibilidade destes pacientes aos vasodilatadores. Além disso, foi determinado o comportamento cinético da NTPDase na presença do vasodilatador que apresentou maior influência inibitória. Os resultados mostraram uma diminuição na atividade da NTPDase na presença de arginina (0,025 mM 3.0 mM), nitroprussiato de sódio (0,01 2,0 mM) e hidralazina (20,0 μM 90,0 μM), quando testada para os substratos ATP e ADP em plaquetas do grupo hipertensos. Porém, a hidrólise dos substratos ATP e ADP aumentou quando testado na presença de arginina no grupo controle. Nenhum efeito foi observado sobre a atividade da enzima quando doses farmacológicas de captopril foram testadas in vitro. Estudos do comportamento cinético foram realizados na presença de nitroprussiato de sódio, o qual causou uma inibição mista. Os valores de Km aumentaram e os de Vmax diminuíram com o aumento da concentração de nitroprussiato de sódio. Os valores de IC50 foram 3,66 mM e 2,64 mM (grupo controle) e 2,08 mM e 3,15 mM (grupo hipertenso) para ATP e ADP, respectivamente. Os valores de Ki obtidos foram 0,167 mM e 0,325 mM para o grupo hipertensos, usando ATP e ADP como substrato, respectivamente. Contudo, baseado nos resultados encontrados, é possível sugerir que existe uma interação entre vasodilatadores, doadores de óxido nítrico e a inibição da hidrólise de nucleotídeos da adenina em plaquetas de pacientes hipertensos.
Mauro, Maria Fernanda Zuliani. "Análise volumétrica da hiperplasia intimal intra-stent farmacológico em pacientes diabéticos tratados com ou sem cilostazol." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/98/98131/tde-04102013-090756/.
Full textBackground: Previous trials with assembled patients in consecutive or random series without blindness offered evidence of the benefit adding cilostazol to the antiplatelet therapy in diabetic patients undergoing drug-eluting stents coronary implantation, with reduction in binary restenosis rates, in-stent late loss and late target lesion revascularization. Objectives: The primary objective of this study was to determine whether the addition of cilostazol to the dual antiplatelet therapy would provide an additional intimal hyperplasia reduction in diabetic patients after drug-eluting stents implantation, measured by calculating the obstruction volume through the intravascular ultrasound 9 months after the index procedure. Secondary objectives were to assess the target vessel quantitative angiography and the occurrence of serious adverse cardiac events (death, nonfatal myocardial infarction and need for a target lesion revascularization) at 30 days, 9 months and 1 year. Methods: Prospective, single center, randomized, double blinded study, gathering 133 diabetic patients, comparing who received cilostazol (Group 1, n= 65) versus placebo (Group 2, n= 68), undergoing coronary stenting, with the releasing of zotarolimus in a native coronary artery with stenosis greater than or equal to 50% and reference diameter equal to or greater than 2.0 mm (visual assessment) with the intravascularultrasound and angiographic restudy at 9 months. Results: Both groups were similar in clinical, angiographic and technical characteristics, except for a higher incidence of arterial hypertension in group 2 (81,5% vs 94,1%, p=0,026) as well as significantly lower coronary stents diameters in group 1 (2,78 mm vs 2,96 mm, p<0,001). The intimal obstruction volume calculated by the intravascularultrasound at 9 months was similar between the groups (33,2% vs 35,1%, p=0,069), as well as the rates of major adverse cardiac events (12,3% vs 8,8%, p= 0,811), stent thrombosis (1,5% versus 0,75%, p= 0,237), in-stent binary restenosis (9,8% vs 6,8%, p= 0,988), in stent late loss (0,60 vs 0,64, p=0,300) and at the segment ( 0,57 vs 0,58, p= 0,387). Conclusions: The addition of cilostazol to the dual antiplatelet therapy with acetylsalicylate acid and clopidogrel, in diabetic patients undergoing stent implantation with zotarolimus did not reduce major adverse cardiac events nor the percentage of intra-stent intimal hyperplasia measured by the intravascularultrasound volumetric analysis.
Cunha, Patrícia Santos. "Efeito vasorelaxante dos isômeros (+) e (-)-linalol em artéria mesentérica de rato." Pós-Graduação em Ciências Fisiológicas, 2013. https://ri.ufs.br/handle/riufs/3972.
Full textLinalol e um monoterpeno que pode ser biossintetizado por algumas plantas na forma racemica, ( })-linalol, ou na forma de enantiomeros, (+)-linalol ou (-)-linalol. A avaliacao da atividade dos isomeros puros tem tornado-se importante para a descoberta de novas drogas com melhor potencial terapeutico e menor indice de efeitos colaterais. Assim, o objetivo do presente estudo foi avaliar a acao vasorelaxante induzida pelos enantiomeros, (+) e (-)-linalol em arteria mesenterica superior de rato, alem de buscar elucidar os mecanismos envolvidos neste efeito. Para tanto, ratos Wistar machos (200 . 300 g) foram sacrificados por dessangramento sob anestesia e a arteria mesenterica superior foi removida. Desta arteria foram obtidos aneis (1-2 mm) que foram mantidos em cubas para orgao isolado contendo 10 mL de solucao nutritiva de Tyrode a 37 oC e gaseificada com carbogenio. Para o registro das contracoes isometricas, cada anel foi suspenso por linha de algodao fixada a um transdutor de forca conectado a um sistema de aquisicao de dados. Em aneis com endotelio funcional pre-contraidos com 10 ÊM fenilefrina, ambos enantiomeros foram capazes de induzir vasorelaxamento significativo dependente da concentracao. Como o efeito apresentado pelo (-)-linalol (Emax = 75 } 3 %; n = 6) foi maior que aquele apresentado pelo (+)-linalol (Emax = 41 } 3 %; n = 4), buscou-se avaliar o mecanismo de acao envolvido em sua acao vasorelaxante. Em aneis sem endotelio funcional, o vasorelaxamento induzido pelo (-)-linalol foi significativamente atenuado em relacao a condicao onde os aneis com endotelio funcional foram pre-contraidos com fenilefrina (Emax = 55 } 1,5 %; n = 5). Resultados semelhantes foram obtidos apos incubacao com 10-8 M de atropina, um antagonista de receptores muscarinicos (Emax = 50 } 5 %; n = 5); ou 10-4 M de L-NAME, um inibidor da sintese de NO (Emax = 57 } 5 %; n = 6); ou 30 ÊM de hidroxocobalamina, um sequestrador de NO (Emax = 45 } 5 %; n = 6). Em aneis sem endotelio funcional pre-incubados com 1 mM de TEA, um bloqueador nao seletivo de canais para K+, o vasorelaxamento induzido pelo (-)-linalol nao foi alterado significativamente (Emax = 70 } 4 %; n = 4). Porem, em aneis sem endotelio funcional pre-contraidos com KCl 80 mM, o vasorelaxamento induzido pelo oleo foi significativamente maior que aquele obtido em aneis sem endotelio funcional pre-contraidos com fenilefrina (Emax = 92 } 2 %; n = 5). Alem disso, concentracoes isoladas de (-)-linalol foram capazes de antagonizar contracoes induzidas por CaCl2 (10-6 . 10-2 M) e Na3VO4 (10-5 . 3 x 10-2 M), um inibidor nao-seletivo de proteinas tirosina-fosfatases. Estes resultados sugerem que os efeitos induzidos pelo linalol ocorrem, principalmente, pela acao de um de seus isomeros, o (-)-linalol. Este isomero produz um efeito vasorelaxante em arteria mesenterica superior de rato que e em parte, dependente do endotelio, o qual se da pela ativacao de receptores muscarinicos e pela liberacao de NO. Alem disso, o vasorelaxamento independente do endotelio e decorrente da inibicao dos canais para calcio sensiveis a voltagem e envolve a sensibilizacao da maquinaria contratil na musculatura lisa vascular.
Martorana, M. G. "Vasodilator aspects of some cardiac inotropic agents." Thesis, University of Strathclyde, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.372098.
Full textMcGinn, Jennifer Sarah. "The vasodilatory and antioxidant activities of polyphenolic substances." Thesis, University of Glasgow, 2002. http://theses.gla.ac.uk/1583/.
Full textReis, Lais Vissotto Garchet Santos. "Efeito da cafeína na detecção de isquemia à cintilografia de perfusão miocárdica associada ao estresse com adenosina." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5131/tde-01022011-162926/.
Full textMyocardial perfusion imaging (MPI) in the past was only available to patients who were able to perform some type of exercise. Many protocols were developed with pharmacologic stress in order to enlarge the clinical availability of myocardial perfusion imaging (MPI). Adenosine is widely used and a potent coronary vasodilator, exhibits a significant interaction with other substances which antagonize its effects, such as dipyridamole, food products containing caffeine and xanthine derivatives. We found no clear consensus as to the time between caffeine ingestion and a cardiovascular adenosine stress test. To test this hypothesis we evaluated the influence of 24-hour, 12-hour and 1-hour caffeine abstinence, by assessing plasma caffeine levels before adenosine pharmacological stress, the possible repercussions on MPI images and vasodilatory effects on the cardiovascular system. The primary endpoint was to compare the presence and extent of reversible myocardial perfusion defects found in patients with 24-hour abstinence from coffee (E1), with images from patients randomized to 1-hour or 12-hour caffeine abstinence (E2). As secondary endpoints we evaluated the presence and intensity of paraeffects, as well as heart rate and systemic arterial blood pressure behavior. For this purpose, 194 patients underwent pharmacological stress with adenosine for MPI, 43 of whom fulfilled criteria for randomization (patients with transient perfusion defects detected on adenosine MPI). Six patients were excluded (13.9%), three patients (6.9%) who refused to undergo randomization, and other three (6.9%) in whom the observers could not reach consensus regarding transient perfusion defects. Mean age for the 37 patients analyzed was 61.4 ± 8.3 years, 21 patients male (56.8%). In the evaluation of myocardial perfusion images, no differences were detected between images obtained in the 24-hour E1 arm, and those from 1 (2.0 ± 1.5) hour or 12 (12.6 ± 3.1) hours randomization E2. Mean plasma caffeine level was 0.14 ± 0.17 mg/l in group E1 of the 1-hour arm E2, and 0.13 ± 0.24 mg/l in group (E1) of the 12-hour arm (E2), respectively, compared with 1.97± 0.83 mg/l, in the 1-hour, and 1.51 ± 1.46 mg/l, in the 12-hour (E2) randomized arms (E1 vs. E2: p < 0.001). In the 31 patients (83.7%) with presence of paraeffects, the most frequent were: atypical precordial pain, tiredness and pain on cervical area. There were no differences in the absolute and relative frequency in the occurrence of paraeffects between groups. However, with respect to the intensity of pareffects, a subjective analysis was undertaken, comparing symptoms of two exams. which resulted in 22 patients (59.4%) ranking the randomized study a lot better, or better than the 24-hour one. The systemic blood pressure and the heart rate behavior also did not reveal any significant differences between groups. Conclusions: The results may imply that the use of caffeine ingested 2 hours prior to the CPM with adenosine was effective and safe, for despite the change in maximal vasodilator response achieved, manifested by better tolerance of the examination with less time in the absence of caffeine in the diet, did not change the final result of the CPM
Shi, Yun. "KATP Channel Phosphorylation: Mechanisms and Contribution to Vascular Tone Regulation by Vasodilating and Vasoconstricting Hormones and Neurotransmitters." unrestricted, 2007. http://etd.gsu.edu/theses/available/etd-11302007-150810/.
Full textTitle from file title page. Chun Jiang, committee chair; Teryl Frey, Deborah Baro, Delon Barfuss, committee members. Electronic text (168 p. : ill. (some col.)) : digital, PDF file. Description based on contents viewed Jan. 30, 2008. Includes bibliographical references (p. 146-151).
Drake, W. M. "Desensitisation of calcitonin gene-related peptide of adrenomedullin receptors in vascular smooth muscle of SK-N-MC cells." Thesis, University of Oxford, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.275192.
Full textBarker, Diana May. "Investigations of the vasodilator actions of corticotrophin-releasing factor." Thesis, Queen Mary, University of London, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299182.
Full textAbu-Kishk, Rabee Awni. "Vasodilator mechanisms and the intracellular control of renin secretion." Thesis, University of Southampton, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.292931.
Full textStride, Ann Elizabeth. "Mechanisms underlying the metabolic and vasodilator effects of insulin." Thesis, University of Birmingham, 2013. http://etheses.bham.ac.uk//id/eprint/4297/.
Full textLove, Alastair I. "Factors affecting nerve regeneration and function in experimental diabetes." Thesis, University of Aberdeen, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241877.
Full textAl-Hamidi, Abdulaziz Abdullah Abdulrahman. "Purification and characterization of prokallikrein from bovine pancreas." Thesis, University of Essex, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.278522.
Full textYang, Yang. "Vascular KATP Channel Modulation by S-Glutathionylation: A Novel Mechanism for Cellular Response to Oxidative Stress." Digital Archive @ GSU, 2011. http://digitalarchive.gsu.edu/biology_diss/97.
Full textCrail, Susan Margaret. "Studies of the function and regulation of vasodilator-stimulated phosphoprotein." Thesis, University of Glasgow, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433088.
Full textSoutherton, J. S. "Studies on the mechanisms of action of some smooth muscle relaxants." Thesis, University of Manchester, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.237287.
Full textPatel, Hanif M. S. "Studies on the nitrosation of thiols in relation to vasodilatory action." Thesis, Durham University, 1989. http://etheses.dur.ac.uk/6728/.
Full textSletten, Nathan Robert. "Effects of high-intensity interval exercise on vasodilator function in children." Thesis, University of British Columbia, 2017. http://hdl.handle.net/2429/62809.
Full textGraduate Studies, College of (Okanagan)
Graduate
Price, Caroline J. "Molecular interactions and cellular functions of the vasodilator stimulated phosphoprotein (VASP)." Thesis, University of Leicester, 2000. http://hdl.handle.net/2381/29350.
Full textTurcato, Sally. "The role of cyclic AMP and K⺠channels in mediating vasorelaxation induced by prostacyclin analogues and other Gs-coupled receptors." Thesis, University College London (University of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342235.
Full textSadigh, Bita. "Analgetic and algetic effects of adenosine in healthy volunteers and patients with coronary artery disease /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-382-5/.
Full textStewart, Derek C. "Implementing formulary recommendations in primary care : effect on patient outcomes." Thesis, Robert Gordon University, 1998. http://hdl.handle.net/10059/615.
Full textDawes, Matthew. "Drug-induced vasodilation in human forearm resistance vasculature." Thesis, King's College London (University of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342326.
Full textGitlin, Jonathan Max. "Endogenous vasodilator pathways : their interactions and relevance to the vascular effects of ATP." Thesis, Imperial College London, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.271969.
Full textDemoncheaux, Eric Arthur Germain. "Physico-chemical properties of nitrogen monoxide : implication for its role as a vasodilator." Thesis, Anglia Ruskin University, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.264045.
Full textCoppock, Hedley Alan. "Investigation of the receptors and mechanisms of action of the novel vasodilator peptide, adrenomedullin." Thesis, Imperial College London, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.327028.
Full textSugita, Kenichiro, Masato Shibuya, Masakazu Takayasu, Yasukazu Kajita, Shin-ichi Satoh, Yoshio Suzuki, and Hirofumi Oyama. "Role of Nitric Oxide in the Cerebral Vasodilatory Responses to Vasopressin and Oxytocin in Dogs." Thesis, Nature Publishing Group, 1993. http://hdl.handle.net/2237/16711.
Full textLovell, Sharon Lynne. "The role of nitric oxide and endothelin in the regulation of pulmonary arterial pressure in man." Thesis, Queen's University Belfast, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322648.
Full textSödergren, Anna. "VASODILATORY EFFECTS OF EXOGENOUS NITRIC OXIDE ON THE BROOD PATCH OF THE ZEBRA FINCH (Taeniopygia guttata)." Thesis, Linköping University, Department of Physics, Chemistry and Biology, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56855.
Full textIn birds like the Zebra finch (Taeniopygia guttata) the female, but not the male develop a brood patch upon incubation of eggs. The brood patch functions to increase heat exchange between the bird and the eggs. Development of the brood patch includes de-feathering, increased vascularization and edema formation. The increased vascularization is due to the development of arteriovenous anastomoses, AVA. The AVA are thermoregulatory vessels involved in cold induced vasodilation, CIVD, demonstrated to occur in the brood patch. Nitric oxide, NO, which is a well known vasodilator is a candidate substance for involvement in CIVD. In this study a NO-generating gel was applied to the brood patch of male and female zebra finches. Vasodilation was found to be markedly larger in females than in males. The larger vasodilation in the female brood patch is probably because NO vasodilate AVA selectively more than any other vessels. The study also investigated whether vasodilation would cause an increase in brood patch temperature. No definite changes in brood patch temperature could be observed and no conclusions could be drawn in the matter.